SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage
biopharmaceutical company focused on developing life-changing
medicines for patients with severe rare diseases and cancer, today
announced initial clinical data from the Phase 1/2 study evaluating
nirogacestat, SpringWorks’ investigational gamma secretase
inhibitor, in combination with BLENREP (belantamab mafodotin-blmf),
GSK plc’s (LSE/NYSE: GSK) antibody drug conjugate targeting B-cell
maturation agent (BCMA), in patients with relapsed or refractory
multiple myeloma (RRMM). In addition, SpringWorks also highlighted
long-term follow-up data from a Phase 2 study sponsored by the
National Cancer Institute (NCI) evaluating nirogacestat in patients
with progressing desmoid tumors, which included follow-up on
progression-free survival and long-term safety data.2 These data
sets will be shared in poster sessions at the 2022 American Society
of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022 in
Chicago.
“We are encouraged by the emerging clinical profile of
nirogacestat with low-dose BLENREP given the promising efficacy and
safety profile that we have seen to date, and we look forward to
the maturation of the Phase 2 portion of the study in parallel with
the initiation of new sub-studies to evaluate this combination with
standard of care treatments in multiple myeloma,” said Saqib Islam,
Chief Executive Officer of SpringWorks. “I would also like to thank
the NCI for their commitment to evaluating nirogacestat in patients
with progressing desmoid tumors. We were very pleased to recently
report positive topline data from our Phase 3 DeFi trial and these
follow-up data from the NCI-sponsored Phase 2 study provide
valuable information on the long-term safety and efficacy profile
of nirogacestat in desmoid tumor patients.”
Synergistic Effects of Low-Dose Belantamab Mafodotin in
Combination with a Gamma-Secretase Inhibitor (Nirogacestat) in
Patients with Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5
Study (Poster # 443)
The objective of this sub-study of GSK’s DREAMM-5 platform trial
(NCT04126200) is to determine if low-dose BLENREP in combination
with nirogacestat results in similar efficacy with an improved
ocular toxicity profile compared to single-agent BLENREP at its
approved dose and schedule. The study opened with a
dose-exploration (DE) arm evaluating 0.95 mg/kg BLENREP Q3W
combined with 100 mg BID nirogacestat dosed continuously, and
subsequently moved into a cohort expansion (CE) arm. The target
enrollment for the CE arm of the study is 70 patients randomized
either to BLENREP 2.5mg/kg Q3W monotherapy (control arm) or
low-dose BLENREP plus nirogacestat combination using the same dose
as the DE arm cohort.
The following results of the pre-planned interim analysis will
be presented at ASCO:
- The study enrolled patients with relapsed or refractory
multiple myeloma who have received at least 3 prior lines of
therapy (median: 4.5), including an immunomodulatory agent,
proteasome inhibitor, and anti-CD38 antibody. The poster being
presented at ASCO includes data from a total of 24 patients treated
with low-dose BLENREP + nirogacestat across the DE and CE cohorts
(N=10 and N=14, respectively) and 14 patients treated with
monotherapy BLENREP in the CE cohort.
- At the time of the March 4, 2022 data cut-off, the median
(range) of follow-up in the low-dose BLENREP plus nirogacestat DE
cohort was 34.5 weeks (5-88 weeks), with durations of response
exceeding one year in some patients. Data from the CE cohorts are
not yet mature with a median duration of follow-up of 12 weeks
available at the time of data cut-off.
- The CE cohorts utilized the KVA ocular toxicity grading scale;
Grade 3 ocular adverse events occurred in 1/14 (7%) patients in the
low-dose BLENREP plus nirogacestat combination compared to 7/14
patients (50%) in the BLENREP monotherapy arm. The DE cohort
utilized the CTCAE-5 ocular toxicity grading scale; the low-dose
BLENREP plus nirogacestat combination demonstrated Grade 3 ocular
adverse events in 2/10 (20%) patients.
- At the time of data cut-off, the objective response rate (ORR)
of low-dose BLENREP plus nirogacestat across the DE and CE cohorts
was 38%, with 17% of patients achieving a VGPR or better (N=24).
The ORR of the BLENREP monotherapy control arm was 50%, with no
patients achieving a VGPR or better (N=14).
These data will be presented in a poster discussion session at
ASCO on June 4, 2022 from 5:30 - 7:00 p.m. EDT by Sagar Lonial, MD,
FACP, Professor and Chair Department of Hematology and Medical
Oncology, Winship Cancer Institute, Emory University.
Extended Progression-Free Survival and Long-Term Safety
of Nirogacestat in Patients with Desmoid Tumors (Poster
#449)
The primary objective of this open-label, NCI-sponsored Phase 2
study (NCT01981551) was to assess the RECIST 1.1-determined
objective response rate of nirogacestat in patients with
progressing desmoid tumors. Seventeen adult patients received 150
mg BID of nirogacestat dosed continuously.
The following results will be presented at ASCO:
- Of the 16 evaluable patients, no disease progression has been
observed for any patient while on study.
- The median time on treatment for all evaluable patients was 4.4
years (range 0.17-7.99 years) with 4/16 patients remaining on
treatment over 7 years. At the time of the Kummar, et. al
publication,3 the median time on treatment was >25 months
(range: 3-30 months), with 10/16 patients remaining on treatment as
of the publication.
- The adverse event profile was generally consistent with what
was previously reported by Kummar, et. al. Long-term follow-up data
reported one new Grade 3 adverse event of diarrhea and one new
Grade 3 adverse event of fatigue.
These data will be presented in a poster session on June 5, 2022
from 9:00a.m.-12:00p.m. EDT by Geraldine Helen O'Sullivan Coyne,
MD, PhD, Developmental Therapeutics Clinic/Early Clinical Trials
Development Program, Division of Cancer Treatment and Diagnosis,
National Cancer Institute.
About Multiple Myeloma
Multiple myeloma is the second most common blood cancer in the
U.S. and is generally considered treatable, but not curable.4,5 It
originates in the bone marrow and is characterized by abnormalities
in plasma cells that reproduce uncontrollably in the bone marrow
and other disease sites. In the U.S., more than 34,000 people are
estimated to be diagnosed with multiple myeloma this year and
nearly 13,000 people will die from the disease.6 New therapies are
needed as multiple myeloma commonly becomes refractory to available
treatments.7
About Desmoid Tumors
Desmoid tumors are rare, aggressive, locally invasive,
potentially morbid tumors of the soft tissues.8,9 While they do not
metastasize, desmoid tumors are associated with a high rate of
recurrence.9,10,11 Sometimes referred to as aggressive
fibromatosis, or desmoid fibromatosis, these soft tissue tumors can
be serious, debilitating, and in rare cases when vital organs are
impacted, they can be life-threatening.9,12
Desmoid tumors are most commonly diagnosed in patients between
the ages of 20 to 44 years, with a two-to-three times higher
prevalence in females.11,13,14 It is estimated that there are
1,000-1,650 new cases diagnosed per year in the United
States.14,15
Historically, desmoid tumors were treated with surgical
resection, but this approach has become less favored due to a high
recurrence rate after surgery.8,11,16 There are currently no
FDA-approved therapies for the treatment of desmoid tumors.
About Nirogacestat
Nirogacestat is an investigational, oral, selective, small
molecule gamma-secretase inhibitor in Phase 3 clinical development
for desmoid tumors, which are rare and often debilitating and
disfiguring soft-tissue tumors. Gamma secretase cleaves multiple
transmembrane protein complexes, including Notch, which is believed
to play a role in activating pathways that contribute to desmoid
tumor growth.
In addition, gamma secretase has been shown to directly cleave
membrane-bound BCMA, resulting in the release of the BCMA
extracellular domain, or ECD, from the cell surface. By inhibiting
gamma secretase, membrane-bound BCMA can be preserved, increasing
target density while reducing levels of soluble BCMA ECD, which may
serve as decoy receptors for BCMA-directed therapies.
Nirogacestat’s ability to enhance the activity of BCMA-directed
therapies has been observed in preclinical models of multiple
myeloma. SpringWorks is evaluating nirogacestat as a BCMA
potentiator and has eight collaborations with industry-leading BCMA
developers to evaluate nirogacestat in combinations across
modalities, including with an antibody-drug conjugate, two CAR T
cell therapies, four bispecific antibodies and a monoclonal
antibody. SpringWorks has also formed research collaborations with
Fred Hutchinson Cancer Research Center and Dana-Farber Cancer
Institute to further characterize the ability of nirogacestat to
modulate BCMA and potentiate BCMA-directed therapies using a
variety of preclinical multiple myeloma models.
Nirogacestat has received Orphan Drug Designation from the U.S.
Food and Drug Administration (FDA) for the treatment of desmoid
tumors and from the European Commission for the treatment of soft
tissue sarcoma. The FDA also granted Fast Track and Breakthrough
Therapy Designations for the treatment of adult patients with
progressive, unresectable, recurrent or refractory desmoid tumors
or deep fibromatosis.
About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company
applying a precision medicine approach to acquiring, developing and
commercializing life-changing medicines for patients living with
severe rare diseases and cancer. SpringWorks has a differentiated
targeted oncology portfolio of small molecule product candidates
and is advancing 18 development programs, including two potentially
registrational clinical trials in rare tumor types as well as
several programs addressing highly prevalent, genetically defined
cancers. SpringWorks’ strategic approach and operational excellence
in clinical development have enabled it to rapidly advance its two
lead product candidates into late-stage clinical trials while
simultaneously entering into multiple shared-value partnerships
with innovators in industry and academia to expand its portfolio
and create more solutions for patients with cancer. For more
information, visit www.springworkstx.com and follow
@SpringWorksTx on Twitter and LinkedIn.
SpringWorks Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
relating to our business, operations, and financial conditions,
including but not limited to current beliefs, expectations and
assumptions regarding the future of our business, future plans and
strategies, our development plans, our preclinical and clinical
results, and other future conditions. Words such as, but not
limited to, “look forward to,” “believe,” “expect,” “anticipate,”
“estimate,” “intend,” “plan,” “would,” “should” and “could,” and
similar expressions or words, identify forward-looking statements.
New risks and uncertainties may emerge from time to time, and it is
not possible to predict all risks and uncertainties. Any
forward-looking statements in this press release are based on
management’s current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks relating to the
timing for initiation, enrollment, progress and completion of
SpringWorks’ clinical trials or third-party clinical trials of its
product candidates, the timing for expected data readouts from
partners and partners' clinical trials, the expected benefits of
collaborations, the fact that interim results from a clinical study
may not be predictive of the final results of such study or the
results of other ongoing or future studies, whether and when, if at
all, SpringWorks’ product candidates will receive approval from the
U.S. Food and Drug Administration, or FDA, or other foreign
regulatory authorities, uncertainties and assumptions regarding the
impact of the COVID-19 pandemic on SpringWorks’ business,
operations, clinical trials involving its product candidates,
supply chain, strategy, goals and anticipated timelines,
competition from other biopharmaceutical companies, and other risks
identified in SpringWorks’ SEC filings.
Except as required by applicable law, we do not plan to publicly
update or revise any forward-looking statements contained herein,
whether as a result of any new information, future events, changed
circumstances or otherwise. Although we believe the expectations
reflected in such forward-looking statements are reasonable, we can
give no assurance that such expectations will prove to be correct.
Accordingly, readers are cautioned not to place undue reliance on
these forward-looking statements.
For further information regarding the risks, uncertainties and
other factors that may cause differences between SpringWorks’
expectations and actual results, you should review the “Risk
Factors” in Item 1A of Part I of SpringWorks’ Quarterly Report on
Form 10-Q for the quarter ended March 31, 2022, as well as
discussions of potential risks, uncertainties and other important
factors in SpringWorks’ subsequent filings.
Contacts:Kim DiamondVice President,
Communications and Investor Relations Phone: 203-561-1646
Email: kdiamond@springworkstx.com
Samantha Hilson Sandler Director, Investor
Relations Phone: 203-461-5501 Email:
samantha.sandler@springworkstx.com
References
1 Lonial, S., Grosicki, S., Hus, M., et al. Synergistic Effects
of Low-Dose Belantamab Mafodotin in Combination with a
Gamma-Secretase Inhibitor (Nirogacestat) in Patients with
Relapsed/Refractory Multiple Myeloma (RRMM): DREAMM-5 Study. Poster
presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL
and online.
2 O’Sullivan Coyne, G, Kummar, S, Steinberg, S, et al. Extended
progression free survival and long-term safety of nirogacestat
(γ-secretase inhibitor, PF-03084014) in patients with desmoid
tumors. Developmental Therapeutics Clinic/Division of Cancer
Treatment and Diagnosis/ National Cancer Institute. Poster
presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL
and online.
3 Kummar, S, Coyne GO, Do KT, et al. Clinical Activity of the
γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors
(Aggressive Fibromatosis). Journal of Clinical Oncology.
2017;35(14):1561-1569. doi:10.1200/jco.2016.71.1994.
4 CA: A Cancer Journal for Clinicians, Vol. 70, Issue 1, Han/Feb
2020 Pages 7-30.
5 Kazandjian D. Multiple myeloma epidemiology and survival: A
unique malignancy. Semin Oncol. 2016;43(6):676–681.
doi:10.1053/j.seminoncol.2016.11.004.
6 SEER Cancer Facts & Figures 2019. Available at:
https://seer.cancer.gov/statfacts/html/mulmy.html. Accessed May
2022.
7 Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for
relapsed and refractory multiple myeloma. Blood. 2015;125(20)
8 Kasper B, Baumgarten C, Garcia J, et al; Desmoid Working
Group. An update on the management of sporadic desmoid-type
fibromatosis: a European Consensus Initiative between Sarcoma
PAtients EuroNet (SPAEN) and European Organization for Research and
Treatment of Cancer (EORTC)/Soft Tissue and Bone Sarcoma Group
(STBSG). Ann Oncol. 2017;28(10):2399-2408.
9 Penel N, Chibon F, Salas S. Adult desmoid tumors: biology,
management and ongoing trials. Curr Opin Oncol.
2017;29(4):268-274.
10 Xie Y, Xie K, Gou Q, He J, Zhong L, Wang Y. Recurrent desmoid
tumor of the mediastinum: a case report. Oncol Lett.
2014;8(5):2276-2278.
11 Skubitz KM. Biology and treatment of aggressive fibromatosis
or desmoid tumor. Mayo Clin Proc. 2017;92(6):947-964.
12 Joglekar SB, Rose PS, Sim F, Okuno S, Petersen I. Current
perspectives on desmoid tumors: the Mayo Clinic approach. Cancers
(Basel). 2011;3(3):3143-3155.
13 Penel N, Coindre JM, Bonvalot S, et al. Management of desmoid
tumours: a nationwide survey of labelled reference centre networks
in France. Eur J Cancer. 2016;58:90-96.
14 van Broekhoven DLM, Grünhagen DJ, den Bakker MA, van Dalen T,
Verhoef C. Time trends in the incidence and treatment of
extra-abdominal and abdominal aggressive fibromatosis: a
population-based study. Ann Surg Oncol. 2015;22(9):2817-2823.
15 Orphanet Report Series: Rare Diseases collection. Prevalence
and incidence of rare diseases: bibliographic data. Number 1,
January 2022. Accessed April 28, 2022.
https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
16 The Desmoid Tumor Working Group. The management of desmoid
tumors: a joint global evidence-based consensus guideline approach
for adult and pediatric patients. Accessed April 10, 2022.
https://dtrf.org/wp-content/uploads/2020/02/Desmoid_Paper_2018_A4_RL_Web300-1.pdf.
SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
SpringWorks Therapeutics (NASDAQ:SWTX)
Historical Stock Chart
From Apr 2023 to Apr 2024